Impact of ESBL‑producing bacteria on patients with acute pyelonephritis: A study based on patient data from a single hospital

The present study investigated the microbial etiologies and clinical impact of extended‑spectrum β‑lactamase (ESBL)‑producing bacteria according to urine blood cultures from patients with acute pyelonephritis (APN). Data all (age >15 years) who had been hospitalized at a single hospital APN were collected between January, 2010 December, 2018. Overall, 882 included. Patients divided into an ESBL‑producing non‑ESBL‑producing group. In addition, each group was further stratified in accordance positive ESBL sample (U‑ESBL U‑non‑ESBL group) or either samples (UB‑ESBL UB‑non‑ESBL group). 651 (74%) these cases, isolated samples. prevalence (UB‑ESBL) found steadily increase over 9‑year period 6.3 37.8%. male sex [odds ratio (OR), 2.572; 95% confidence interval (CI), 1.295‑5.108] previous antibiotic exposure (OR, 2.275; CI, 1.105‑4.680) significant risk factors for UB‑ESBL multivariable analysis. exhibited significantly higher mortality rate 1.654; 1.106‑2.474) continuous renal replacement therapy (CRRT) rate. By analysis, not U‑ESBL independent prognostic indicator recurrence. Consequently, use carbapenems as first‑line is expected rapidly increase, there concern regarding emergence new antibiotic‑resistance bacteria. Global efforts reduce resistance development novel treatment methods other than antibiotics treat are urgently required. results emphasize importance culture tests, well tests successful APN.